Cargando…

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices

BACKGROUND: Colony-stimulating factors (CSFs) significantly decrease the risk of febrile neutropenia (FN), a common complication of myelo suppressive chemotherapy. Pegfilgrastim (6 mg), introduced in 2002, has a sustained duration of action, with a single dose comparable in efficacy to daily injecti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrison, Vicki A., Wong, Mitchell, Hershman, Dawn, Campos, Luis T., Ding, Beiying, Malin, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2007
Materias:	Formulary Management
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437874/ https://www.ncbi.nlm.nih.gov/pubmed/17506600 http://dx.doi.org/10.18553/jmcp.2007.13.4.337

Ejemplares similares

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
por: Fisher, Vicki S.
Publicado: (2005)

Determinants of the Cost-Effectiveness of Statins
por: Morrison, Alan, et al.
Publicado: (2003)

Pegfilgrastim Versus Filgrastim for Primary Prophylaxis of Febrile Neutropenia in Patients with non-Hodgkin’s Lymphoma: A Cost-Effectiveness Study
por: Ravangard, Ramin, et al.
Publicado: (2017)

Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review
por: Gebremariam, Girma Tekle, et al.
Publicado: (2022)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma
por: Cerchione, Claudio, et al.
Publicado: (2021)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
por: Payakachat, Nalin, et al.
Publicado: (2006)

Cost-Effectiveness Analysis and the Formulary Decision-Making Process
por: Wang, Zhixiao, et al.
Publicado: (2004)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Health Plan Budget Impact Analysis for Pimecrolimus
por: Chang, Jane, et al.
Publicado: (2005)

Multicenter Drug Use Evaluation of Tamsulosin and Availability of Guidance Criteria for Nonformulary Use in the Veterans Affairs Health System
por: Burk, Muriel, et al.
Publicado: (2004)

Similar Medication Compliance and Control of Dyslipidemia WithSimvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic
por: Valdez, Connie A., et al.
Publicado: (2005)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

Proton-Pump Inhibitor Utilization Associated With the Change to Nonpreferred Formulary Status for Esomeprazole in the TRICARE Formulary
por: Linton, Andrea, et al.
Publicado: (2009)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
por: Billups, Sarah J., et al.
Publicado: (2005)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
por: Ramsey, Scott D., et al.
Publicado: (2006)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013)

Comparison of Risedronate to Alendronate and Calcitonin for Early Reduction of Nonvertebral Fracture Risk: Results From a Managed Care Administrative Claims Database
por: Watts, Nelson B., et al.
Publicado: (2004)

A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System
por: Belperio, Pamela S., et al.
Publicado: (2014)

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
por: Campbell, Helen Eloise
Publicado: (2005)

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
por: Gershovich, Olga E., et al.
Publicado: (2006)

Drug and Medical Cost Effects of a Drug Formulary Change With Therapeutic Interchange for Statin Drugs in a Multistate Managed Medicaid Organization
por: Meissner, Brian, et al.
Publicado: (2006)

Managed Care Perspective on Three New Agents for Type 2 Diabetes
por: VanDeKoppel, Shawna, et al.
Publicado: (2008)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration
por: Hong, Song Hee, et al.
Publicado: (2005)

AMCP Format Dossier Requests: Manufacturer Response and Formulary Implications for One Large Health Plan
por: Spooner, Joshua J., et al.
Publicado: (2007)

Industry's Perception of Presenting Pharmacoeconomic Models to Managed Care Organizations
por: Olson, Bridget M., et al.
Publicado: (2003)

Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative Claims Data
por: Meryer, Christina
Publicado: (2003)

Do Decision-Analytic Models Identify Cost-Effective Treatments? A Retrospective Look at Helicobacter Pylori Eradication
por: Fairman, Kathleen A., et al.
Publicado: (2003)

Alternate Financial Incentives in Multi-tiered Formulary Systems to Improve Accountability for Outcomes
por: Chung, Richard S., et al.
Publicado: (2003)

Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES
por: Ofman, Joshua J., et al.
Publicado: (2003)

Formulary Review of 2 New Biologic Agents: Tocilizumab for Rheumatoid Arthritis and Ustekinumab for Plaque Psoriasis
por: Schafer, Jeremy A., et al.
Publicado: (2010)

A Comparison of the Cost-Effectiveness of Almotriptan and Sumatriptan in the Treatment of Acute Migraine Using a Composite Efficacy/Tolerability End Point
por: Williams, Paul, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_hg2scj12evcl54mna1rbvd5k4n